Clinical trials: Placebo Effect
Pulmonary Hypertension
Targeting the Right Ventricle in Pulmonary Hypertension
This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension specific therapies but with right ventricular dysfunction (RVEF <45%) would improve their outcome.
- Trial name
- NCT01839110
- Testing
- Ranolazine
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Chronic Kidney Disease
Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
This research is studying how Vitamin D may affect blood vessels reaction to stress and blood levels of substances that may increase blockages in the blood vessels in chronic kidney disease (CKD) patients.
- Trial name
- NCT00915876
- Testing
- Paricalcitol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Amy Barton Pai
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive Change
Examining the Effectiveness of Cognitive Training
The present study addresses whether placebo effects can possibly account for previous findings in the field, as well as ascertains whether placebo-based mechanisms can be deliberately harnessed for impact.
- Trial name
- NCT04344028
- Testing
- True Cognitive Training Program, Control Cognitive Training Program, Positive Expectation Induction
- Where
- 3 sites in United States
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Progressive Multiple Sclerosis, Fatigue
A Study of Oxidative Pathways in MS Fatigue
This is a 4-week randomized, placebo-controlled, parallel group, double-blind, single center trial on effect of N-acetyl cysteine versus placebo on fatigue in patients with progressive MS defined by McDonald criteria.
- Trial name
- NCT02804594
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Healthy
Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.
The objective of this study is to evaluate the effect of multiple doses of BI 207127 combined with faldaprevir on cardiac safety parameters in healthy subjects
- Trial name
- NCT01965431
- Testing
- BI 207127, Faldaprevir, Moxifloxacin (Avalox®)
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.
- Trial name
- NCT01205269
- Testing
- AZD8683, 50 mcg, AZD8683, 200 mcg
- Where
- 4 sites in Poland
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Attention Deficit/Hyperactivity Disorder(ADHD)
Effect of Vyvanse on Driving in Young Adults With ADHD
The primary objective of the study is to assess the benefice of Vyvanse on the factors that cause impairments in driving behavior in individuals with ADHD using a driving simulation aimed at examining the factors that cause…
- Trial name
- NCT00801229
- Testing
- Vyvanse
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Asthma
Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled…
- Trial name
- MESOS (NCT02449473)
- Testing
- Tralokinumab
- Where
- 15 sites in Canada, Denmark and 1 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.
- Trial name
- NCT05879718
- Testing
- PF-06823859
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Pfizer
Cystic Fibrosis
NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients
This Phase IIB proof-of-concept study would examine the effects of an investigational product called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung disease.
- Trial name
- NCT00809094
- Testing
- N-acetylcysteine (NAC)
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This 4 arm study in patients with advanced Stage IIIb/IV non-small cell cancer (NSCLC) who failed at least one standard chemotherapy regimen will determine the proportion of patients with progression-free survival at 12 weeks…
- Trial name
- NCT00760929
- Testing
- RG1507, erlotinib [Tarceva]
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease, COPD
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.
- Trial name
- NCT01708057
- Testing
- AZD8683, Tiotropium
- Where
- 6 sites in Poland, Sweden
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT04140695
- Testing
- Tradipitant
- Where
- 51 sites in United States
- Volunteers
- 87 people
- Sponsor
- Vanda Pharmaceuticals
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Dementia
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.
- Trial name
- NCT01059877
- Testing
- 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Quietmind Foundation
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
- Trial name
- NCT02004886
- Testing
- MK-0893, Metformin
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Prurigo Nodularis
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
The main objective of this study is to assess the long-term durability of response over a 24-week period following withdrawal of nemolizumab in participants with prurigo nodularis (PN) who previously responded to treatment in the…
- Trial name
- NCT05052983
- Testing
- Nemolizumab
- Where
- 14 sites in United States, Austria and 5 more
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.